...
机译:Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Guangdong Lung Canc Inst,Guangdong Prov Peoples Hosp;
Dept Thorac Oncol,Jilin Prov Tumor Hosp;
Dept Med Oncol,First Hosp China Med UnivMed Oncol,Canc Hosp Harbin Med UnivCanc Ctr,First Hosp Jilin UnivDept Med Oncol,Hunan Canc HospJinling Hosp,Nanjing Univ Sch MedMed Oncol,Liaoning Canc HospShanghai Chest Hosp,Shanghai Jiao Tong UnivAffiliated Hosp 1,Zhejiang UnivDept Resp Med,Zhengzhou UnivTongji Hosp,Huazhong Univ Sci & TechnolMed Oncol,Fujian Canc HospAffiliated Hosp 1,Nanjing Med Univ;
CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; 1ST-LINE THERAPY; OPEN-LABEL; XENOGRAFT MODELS; CHEMOTHERAPY; BRAIN; SURVIVAL; ANGIOGENESIS; CARBOPLATIN;